Phase 2 study of eprenetapopt plus azacitidine for TP53-mutated MDS and AML

Prof. Pierre Fenaux

A multicenter phase 2 study in France evaluated the combination of eprenetapopt plus azacitidine for previously untreated TP53-mutated MDS and AML. The outcomes were better than what has been seen with azacitidine monotherapy.